Prof. Dr. med. Thomas Longerich
Stellv. Ärztlicher Direktor
(Allgemeine Pathologie und Pathologische Anatomie)
Leitender Oberarzt
(Allgemeine Pathologie und Pathologische Anatomie)
Arbeitsgruppenleiter
(AG Longerich)
Clinical Lead
(Translational Spatial Profiling Center (TSPC))
Studienleiter LCCH-Registerstudie
Ärztlicher / Beruflicher Werdegang
- seit 2017
Professor of General Pathology, Institute of Pathology, University of Heidelberg
- 2016 – 2017
Executive Senior Physician, Deputy Head, Institute of Pathology, RWTH Aachen
- 2015 – 2017
Head NGS Diagnostics, Institute of Pathology and Deputy Head, Center for NGS Diagnostics, University Hospital RWTH Aachen
- 2014 – 2017
Professor of Oncological Pathology, Institute of Pathology, University Hospital RWTH Aachen (head: Prof. Ruth Knüchel-Clarke)
- 2012 – 2014
Consultant Pathologist, Institute of Pathology, University of Heidelberg
- 2010 – 2012
Consultant Pathologist for Hepatopathology, Institute of Pathology, University of Heidelberg
- 2009
Board Certification in Pathology
- seit 2007
Research group leader
Wissenschaftlicher Werdegang
- 2011
Postdoctoral Lecture Qualification (Habilitation)
- 2003
MD-Thesis, Institute of Pathology, University of Cologne (magna cum laude; supervised by Prof. Dr. P. Schirmacher)
- 1995 – 2002
Study of Medicine, University of Cologne
Auszeichnungen
- 2014
Distinguished Clinical Study 2014 “Efficacy and Non-Target Effects of TACE in Bridging of HCC Patients to Liver Transplantation - a Histopathological Study”; Journal of Vascular and Interventional Radiology.
- 2014
Virchow Price, German Society of Pathology
- 2011
Poster award, 27th Annual Meeting of the German Association for the Study of Liver disease (GASL), Regensburg; ”Metabolism, Transport, Tumors”
Mitgliedschaften
- seit 2015
Deputy Coordinator of the Working Group Molecular High Troughput Diagnostic, German Society for Digestive and Metabolic Diseases
- 2013
Member of the Laennec Liver Pathology Society
Selected Publications
Mueller C, Waldburger N, Stampfl U, Kauczor HU, Schirmacher P, Sommer CM, Longerich T (2017) Non-invasive diagnosis of hepatocellular carcinoma revisited.Gut. 2017 Sep 12. pii: gutjnl-2017-314981. doi: 10.1136/gutjnl-2017-31498
Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, Ringelhan M, Connor TO, Stadler M, Meister M, Weber J, Ollinger R, Simonavicius N, Reisinger F, Hartmann D, Meyer R, Reich M, Seehawer M, Leone V, Hochst B, Wohlleber D, Jors S, Prinz M, Spalding D, Protzer U, Luedde T, Terracciano L, Matter M, Longerich T, Knolle P, Ried T, Keitel V, Geisler F, Unger K, Cinnamon E, Pikarsky E, Huser N, Davis RJ, Tschaharganeh DF, Rad R, Weber A, Zender L, Haller D, Heikenwalder M (2017) Kupffer Cell
-Derived Tnf Triggers Cholangiocellular Tumorigenesis through JNK due to Chronic Mitochondrial Dysfunction and ROS. Cancer Cell 31:771-789 e776.Mueller S, Nahon P, Rausch V, Peccerella T, Silva I, Yagmur E, Straub BK, Lackner C, Seitz HK, Rufat P, Sutton A, Bantel H, Longerich T (2017) Caspase-cleaved keratin-18 fragments increaseduring alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease. Hepatology 66:96-107.
Schneider AT, Gautheron J, Feoktistova M, Roderburg C, Loosen SH, Roy S, Benz F, Schemmer P, Buchler MW, Nachbur U, Neumann UP, Tolba R, Luedde M, Zucman-Rossi J, Panayotova-Dimitrova D, Leverkus M, Preisinger C, Tacke F, Trautwein C, Longerich T, Vucur M, Luedde T (2017) RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell 31:94-109.
Endig J, Buitrago-Molina LE, Marhenke S, Reisinger F, Saborowski A, Schutt J, Limbourg F,Konecke C, Schreder A, Michael A, Misslitz AC, Healy ME, Geffers R, Clavel T, Haller D, UngerK, Finegold M, Weber A,Manns MP, Longerich T, Heikenwalder M, Vogel A (2016) Dual Role of the Adaptive Immune System in Liver Injury and Hepatocellular Carcinoma Development. Cancer Cell 30:308-323.
Elgohary N, Pellegrino R, Neumann O, Elzawahry HM, Saber MM, Zeeneldin AA, Geffers R,Ehemann V, Schemmer P, Schirmacher P, Longerich T (2015) Protumorigenic role of Timelessin hepatocellular carcinoma. Int J Oncol 46:597-606
Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L (2014) In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 20:1138-1146.
Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, Longerich T, Enikolopov G, Lowe SW (2014) p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158:579-592.
Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, LaduS, Elgohary N, Bermejo JL, Radlwimmer B, Zornig M, Zender L, Dombrowski F, Evert M, Schirmacher P, LongerichT (2014) EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology 59:1886-1899.
Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P, Schirmacher P, Bermejo JL, Longerich T (2012) Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 56:1817-1827.